Literature DB >> 9327497

Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck.

M T Sheridan1, T O'Dwyer, C B Seymour, C E Mothersill.   

Abstract

Recently, attention has focused on the potential of oncogenes, tumour suppressor genes, and assessment of cell proliferation as biological response indicators in human cancer. In this study, immunocytochemical analysis was used to evaluate the usefulness of Ki67, epidermal growth factor receptor (EGFr), and the protein products of c-Myc and Bcl-2 as indicators of radiosensitivity in primary cultures of head and neck tumours. Primary cultures established from tumours taken at surgery were divided into two groups; the control group remained untreated, and the treatment group received a single dose of 2 Gy. The cultures were incubated for 14 days, after which time they were fixed and examined immunocytochemically. The response to treatment of the cultures was measured as the percentage of growth inhibition (%GI) in the treated cultures relative to the untreated controls. Expression of Ki67 measured after a single dose of 2 Gy significantly differentiated the radioresistant and radiosensitive groups (P = 0.045); high percentages of Ki67+ cells correlated with radioresistance. A significant difference was found between the expression of EGFr in the resistant and sensitive groups, as measured in control cultures and after a dose of 2 Gy (P = 0.002 and P = 0.03, respectively); high levels of expression of EGFr correlated with radioresistance. The level of expression c-Myc+ cells, as measured in control cultures, significantly distinguished the radiosensitive group from the radioresistant group (P = 0.05). These results indicate a potential role for these proteins as indicators of radioresistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327497     DOI: 10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.0.CO;2-U

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  30 in total

Review 1.  Lessons learned from radiation oncology clinical trials.

Authors:  Fei-Fei Liu; Paul Okunieff; Eric J Bernhard; Helen B Stone; Stephen Yoo; C Norman Coleman; Bhadrasain Vikram; Martin Brown; John Buatti; Chandan Guha
Journal:  Clin Cancer Res       Date:  2013-09-16       Impact factor: 12.531

2.  Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.

Authors:  Tim J Kruser; Eric A Armstrong; Amol J Ghia; Shyhmin Huang; Deric L Wheeler; Robert Radinsky; Daniel J Freeman; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

3.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 4.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

5.  AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Authors:  Mylin A Torres; Uma Raju; David Molkentine; Oliver Riesterer; Luka Milas; K Kian Ang
Journal:  Invest New Drugs       Date:  2010-02-02       Impact factor: 3.850

Review 6.  Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.

Authors:  Bipasha Mukherjee; Hak Choy; Chaitanya Nirodi; Sandeep Burma
Journal:  Semin Radiat Oncol       Date:  2010-10       Impact factor: 5.934

7.  Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.

Authors:  Arti Yadav; Bhavna Kumar; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2011-05-06       Impact factor: 6.261

Review 8.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Barbara A Burtness
Journal:  Clin Adv Hematol Oncol       Date:  2008-10

9.  The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.

Authors:  Anjali K Gupta; Bin Li; George J Cerniglia; Mona S Ahmed; Stephen M Hahn; Amit Maity
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

Review 10.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Authors:  Pinaki R Dutta; Amit Maity
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.